Radiologic and Clinical Correlates of Long-Term Post-COVID-19 Pulmonary Sequelae

Görkem Durak, Kaan Akın, Okan Çetin, Emre Uysal, Halil Ertugrul Aktas, Ülkü Durak, Ahmet Yasin Karkaş, Naci Şenkal, Hatice Savas, Atadan Tunacı, Alpay Medetalibeyoğlu, Ulaş Bağcı, Şükrü Mehmet ErtürkJournal of Clinical Medicine 2025 · DOI

TL;DR

This study investigated the long-term lung changes (sequelae) after moderate-to-severe COVID-19 pneumonia using CT scans and clinical data from 93 patients. They found that while many imaging abnormalities persist, particularly fibrotic-like changes, a significant portion of non-fibrotic changes can resolve over time, and initial CT severity and LDH levels are predictors of these persistent findings.

What Problem Does This Paper Address?

The long-term consequences of COVID-19, often termed "long COVID," are a significant health concern, impacting various organ systems and quality of life. While acute COVID-19 pneumonia's radiologic patterns are well-documented, there's a considerable knowledge gap regarding the persistence of these lung abnormalities over time and their correlation with ongoing clinical symptoms. Understanding these chronic changes is crucial for developing effective follow-up strategies, managing patient care, and potentially reducing healthcare burdens. This paper aims to bridge this gap by systematically analyzing long-term pulmonary sequelae and their relationship to clinical and laboratory data.

Methods

The researchers conducted a retrospective, single-center observational study involving 93 patients admitted to Istanbul Medical Faculty Hospital with moderate-to-severe COVID-19 pneumonia.

  • CT Scans: Patients underwent at least two chest CT scans: one during initial hospitalization and another at a follow-up visit approximately ten months later. A subcohort of 46 patients also had mid-term scans (5-7 months post-infection).
  • Radiologic Assessment: Two thoracic radiologists independently assessed initial CT scans using a semi-quantitative volumetric scoring system (0-25) to quantify lung involvement. For follow-up scans, the same radiologists, along with a pulmonologist, retrospectively reviewed findings for persistence, progression, or new developments, without knowledge of clinical data. They categorized findings into "non-fibrotic" (e.g., ground-glass opacities, heterogeneous attenuation) and "fibrotic-like" (e.g., pleuroparenchymal bands, fine reticulation).
  • Clinical and Laboratory Data: Demographic information, BMI, and laboratory results (lymphocytes, platelets, CRP, LDH, ferritin, D-dimer, troponin) from the time of diagnosis were collected. Patients were also questioned about persistent symptoms like fatigue, dyspnea, chest pain, muscle pain, and cough during follow-up.
  • Statistical Analysis: Various statistical tests (Mann-Whitney U, chi-squared, Fisher's exact, McNemar's, logistic regression) were employed to correlate imaging findings with clinical and laboratory data, identify predictors of persistent changes, and compare mid-term and long-term findings.

Datasets

The study utilized data from 93 patients hospitalized with moderate-to-severe COVID-19 pneumonia at Istanbul Medical Faculty Hospital between March 2020 and April 2022. This dataset included:

  • Chest CT scans (initial and follow-up).
  • Clinical data (demographics, symptoms, comorbidities).
  • Laboratory data (blood test results).

No new benchmark datasets were introduced.

Key Insights and Ideas

  • Persistence is Common, but Resolution Happens: While a significant proportion of patients exhibit persistent lung abnormalities (non-fibrotic in 36.6%, fibrotic-like in 75.3% at long-term follow-up), the study highlights that non-fibrotic changes, especially, show a tendency to lessen over time, with notable improvement observed between 5-7 months post-infection.
  • Predictors of Persistence: Initial CT severity score and serum LDH levels emerged as significant predictors for both non-fibrotic and fibrotic-like imaging changes at long-term follow-up. This suggests that the initial severity of lung involvement and markers of inflammation/tissue damage are crucial indicators of future chronic changes.
  • Clinical Correlations Exist, but Nuanced: Persistent non-fibrotic changes were associated with higher rates of fatigue and chest pain, while fibrotic-like changes were linked to chest pain. This indicates a tangible link between imaging findings and patient-reported symptoms, though the correlations are not always straightforward.
  • "Fibrotic-like" is a Useful Descriptor: The study reinforces the utility of the term "fibrotic-like changes" to describe scarring patterns that are potentially more permanent, distinguishing them from acute inflammatory changes.

Key Results

  • Prevalence of Persistent Findings: At approximately 10 months post-infection, 36.6% of patients had persistent non-fibrotic changes (most commonly heterogeneous attenuation and GGOs), and 75.3% had persistent fibrotic-like changes (most commonly pleuroparenchymal bands/linear atelectasis, fine reticulation, and subpleural curvilinear lines).
  • Regression: In the subcohort of 46 patients with mid- and long-term follow-up, 47.2% of non-fibrotic changes regressed, while only 10% of fibrotic-like changes regressed over the long term.
  • Statistical Correlations:
    • Persistent non-fibrotic and fibrotic-like changes were statistically correlated with initial CT score (p < 0.001), LDH (p < 0.001), and ferritin levels (p = 0.008 and p = 0.003, respectively).
  • Fatigue (p = 0.025) and chest pain (p < 0.001) were more frequent with persistent non-fibrotic changes.
  • Chest pain (p = 0.033) was more frequent with persistent fibrotic-like changes.
  • Multivariable Predictors: Initial CT severity score (p = 0.020) and serum LDH level (p = 0.009) were independent predictors of fibrotic-like imaging changes. For non-fibrotic changes, initial CT severity score (p = 0.010), serum LDH level (p = 0.007), and chest pain at presentation (p = 0.049) were predictors.

Limitations and Future Work

  • Limitations:
    • Retrospective, Single-Center Study: This design inherently limits generalizability.
  • Small Cohort Size: The study included 93 patients, which is relatively small for drawing definitive conclusions.
  • Lack of Standardized Criteria: The absence of universally standardized criteria for moderate-to-severe COVID-19 pneumonia classification makes direct comparison with other studies challenging.
  • Selection Bias: The focus on moderate-to-severe cases, while addressing a higher-risk group, introduces selection bias.
  • Incomplete Documentation: Treatment details and specific SARS-CoV-2 variants were not consistently documented, limiting analysis.
  • No Expiratory CT: Expiratory HRCT, useful for assessing small airway damage, was not performed.
  • Vaccination Status Not Controlled: The impact of vaccination on imaging findings was not analyzed.
  • Future Work:
    • Larger, Multicenter Cohorts: Future research should involve larger, diverse patient populations to enhance generalizability.
  • Longer Follow-up Periods: Extended follow-up is needed to fully understand the trajectory of these changes.
  • Comprehensive Smoking History: Including smoking history in future studies is crucial, as it's a known confounder for pulmonary outcomes.
  • Objective Symptom Assessment: Future studies could benefit from more objective symptom assessments.
  • Vascular Complications: Investigating vascular complications, such as pulmonary embolism, using appropriate imaging techniques would be valuable.
  • Causality and Clinical Implications: Further investigation is needed to establish causality between imaging patterns and clinical outcomes and to refine patient management strategies.

Summary updated

Abstract

<b>Background/Objectives</b>: The long-term sequelae of COVID-19 pneumonia, particularly the persistence of imaging abnormalities and their relationship to clinical symptoms, remain unclear. While the acute radiologic patterns are well-documented, the transition to chronic pulmonary changes-and their implications for long COVID symptoms-require systematic investigation. <b>Methods</b>: Our study included 93 patients with moderate to severe COVID-19 pneumonia who were admitted to Istanbul Medical Faculty Hospital, each having one follow-up CT scan over a ten-month period. Two thoracic radiologists independently calculated semi-quantitative initial chest CT scores to evaluate lung involvement in pneumonia (0-5 per lobe, total score 0-25). Two radiologists and one pulmonologist retrospectively examined the persistence of follow-up imaging findings, interpreting them alongside the relevant clinical and laboratory data. Additionally, in a subcohort (<i>n</i> = 46), mid-term (5-7 months) and long-term (≥10 months) scans were compared to assess temporal trajectories. <b>Results</b>: Among the 93 patients with long-term follow-up imaging, non-fibrotic changes persisted in 34 scans (36.6%), while fibrotic-like changes were observed in 70 scans (75.3%). The most common persistent non-fibrotic changes were heterogeneous attenuation (29%, <i>n</i> = 27) and ground-glass opacities (17.2%, <i>n</i> = 16), and the persistent fibrotic-like changes were pleuroparenchymal bands or linear atelectasis (58%, <i>n</i> = 54), fine reticulation (52.6%, <i>n</i> = 49), and subpleural curvilinear lines (34.4%, <i>n</i> = 32). Both persistent non-fibrotic and fibrotic-like changes were statistically correlated with the initial CT score (<i>p</i> < 0.001), LDH (<i>p</i> < 0.001), and ferritin levels (<i>p</i> = 0.008 and <i>p</i> = 0.003, respectively). Fatigue (<i>p</i> = 0.025) and chest pain (<i>p</i> < 0.001) were reported more frequently in patients with persistent non-fibrotic changes, while chest pain (<i>p</i> = 0.033) was reported more frequently among those with persistent fibrotic-like changes. Among the 46 patients who underwent both mid- and long-term follow-up imaging, 47.2% of those with non-fibrotic changes (17 out of 36) and 10% of those with fibrotic-like changes (4 out of 40) exhibited regression over the long term. <b>Conclusions</b>: Initial imaging and laboratory findings may indicate persistent imaging findings related to long-term sequelae of COVID-19 pneumonia. Many of these persistent imaging abnormalities, particularly non-fibrotic changes seen in the mid-term, tend to lessen over the long term. A correlation exists between persistent imaging findings and clinical outcomes of long COVID-19, underscoring the need for further research.
BibTeX
@article{durak2025radiologic,
  author = {Görkem Durak and Kaan Akın and Okan Çetin and Emre Uysal and Halil Ertugrul Aktas and Ülkü Durak and Ahmet Yasin Karkaş and Naci Şenkal and Hatice Savas and Atadan Tunacı and Alpay Medetalibeyoğlu and Ulaş Bağcı and Şükrü Mehmet Ertürk},
  title = {{Radiologic and Clinical Correlates of Long-Term Post-COVID-19 Pulmonary Sequelae}},
  journal = {Journal of Clinical Medicine},
  year = {2025},
  doi = {10.3390/jcm14144874},
}
Figure